BioNTech SE ADR BNTX
News
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
BioNTech Cancer Treatment Gets US FDA Fast Track Designation
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
New U.S. bird-flu case is first with respiratory symptoms, CDC says
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnership
Moderna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., Australia
BioNTech Up Over 8%, on Pace for Largest Percent Increase Since October 2022 — Data Talk
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
BioNTech Down Over 8%, On Track for Lowest Close Since January 2021 — Data Talk
BioNTech's stock sinks after earnings miss, as inventory writedowns weigh
BioNTech Profit Slumps on Lower Covid Vaccine Sales